ClinicalTrials.gg
RecruitingNCT07240662VIOLETAUpdated Jan 9, 2026

Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse Glioma

An observational study in Glioma, sponsored by iOMEDICO AG. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by iOMEDICO AG · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Glioma with a site in Germany — 20 open to participants now, 29 under way, 3 of them phase 3. Glioma · Germany.

Planned enrollment
6th of 11
150 · median 150
Started
2025
with 6 others
Observational
11 of 70
6 open now
Primary completion
2031-11
later than 26 of 28 live
Registered
66th of 70
by date

Among the 70 studies in Glioma with a site in Germany, this one is the 6th largest by planned enrollment of the 11 observational ones that give a count, is one of 7 that started in 2025, is one of 11 observational ones, reaches primary completion later than 26 of the 28 other live ones, and was the 66th registered.

Glioma

1,456 studies on the registry are indexed under Glioma; 351 are open to participants now.

Browse Glioma studies →

Open to participants now

20 of the 70 studies in Glioma with a site in Germany are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Glioma with a site in Germany, or all of them as a file.
02

Study summary

The goal of this prospective, observational study VIOLETA is to collect real-world data on vorasidenib treatment in a broad patient population. Though vorasidenib can be administered from 12 years old, VIOLETA focuses on adult patients with IDH1- or IDH2-mutant WHO grade 2 glioma who receive vorasidenib following surgery according to the current SmPC. Thus, VIOLETA will evaluate for the first-time treatment with vorasidenib in German clinical routine. To gain knowledge about how vorasidenib treatment affects patients' well-being, the primary objective of the study is to assess patients' quality of life. Further patient-relevant endpoints addressed by this study will include seizure burden, PFS, Objective Response Rate (ORR), TTNI, safety as well as factors affecting treatment decision making.

03

Conditions studied

  • Glioma

Browse trials for

Keywords

  • WHO Grade 2
  • IDH-mutant
  • diffuse
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients (at least 40 kg) with predominantly non-enhancing grade 2 astrocytoma or oligodendroglioma with an IDH1 or IDH2 mutation who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • WHO grade 2 astrocytoma or oligodendroglioma
  • Presence of IDH1- or IDH2-mutation
  • Surgical intervention
  • No immediate need of radiotherapy or chemotherapy according to the treating physician
  • Decision for treatment with vorasidenib as per current SmPC
  • Signed written *
  • Willingness to participate in Patient-Reported Outcome (PRO) assessment in German language
  • Other criteria according to current SmPC * Patients are allowed to be enrolled up to 6 weeks after their first intake of vorasidenib but must still be on treatment at the time of enrollment

Exclusion criteria

Exclusion Criteria:

  • Participation in an interventional clinical trial
  • Patient unable to consent
  • Other according to current SmPC.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Interventions

  • oral, first-in-class, dual inhibitor of mIDH 1 and 2

06

What researchers measure

Primary outcomes

  1. Evaluate Quality of Life (QoL) by the Functional Assessment of Cancer Therapy - Brain (FACT-Br) questionnaire over the course of treatment

    Evaluate QoL by the FACT-Br questionnaire over the course of treatment. Change from baseline in the FACT-Br total score over time. The FACT-Br total score ranges from 0 to 200, with higher scores indicating better quality of life.

    Time frame: baseline, up to 72 months

Secondary outcomes

  1. Evaluate Quality of Life (QoL) by using the Functional Assessment of Cancer Therapy - Brain (FACT-Br) questionnaire at start and during course of vorasidenib treatment

    Evaluate QoL by using the FACT-Br questionnaire at start and during course of vorasidenib treatment. Change from baseline over time for all other scales of the FACT-Br. For all scales, the higher the score the better quality of life.

    Time frame: baseline, up to 72 months

  2. Assess seizure activity and severity at baseline and during treatment: Proportion of patients with baseline seizure activity

    Proportion of patients with baseline seizure activity is defined as at least 1 seizure in the previous 30 days prior to vorasidenib treatment start

    Time frame: baseline, up to 72 months

  3. Assess seizure activity and severity at baseline and during treatment: event rate of seizures

    Exposure adjusted event rate of seizures according to patient-reported outcome (patient diary)

    Time frame: baseline, up to 72 months

  4. Assess seizure activity and severity at baseline and during treatment: event rate of seizures with loss of consciousness

    Exposure adjusted event rate of seizures with loss of consciousness according to PRO (patient diary)

    Time frame: baseline, up to 72 months

  5. Assess seizure activity and severity at baseline and during treatment: incidence rate of seizures

    Exposure adjusted incidence rate of seizures according to patient-recorded outcome

    Time frame: baseline, up to 72 months

  6. Assess seizure activity and severity at baseline and during treatment: incidence rate of seizures with loss of consciousness

    Exposure adjusted incidence rate of seizures according to patient-reported outcome

    Time frame: baseline, up to 72 months

  7. Assess seizure activity and severity at baseline and during treatment: Change from baseline of seizures

    Change from baseline of seizures reported by the patients during course of treatment

    Time frame: max. 72 months; from patient-specific study start to end of study (during vorasidenib treatment and follow-up)

  8. Assess seizure activity and severity at baseline and during treatment: Change from baseline of seizures with loss of consciousness

    Change from baseline of seizures with loss of consciousness reported by the patients during course of treatment

    Time frame: baseline, up to 72 months

  9. Assess effectiveness in routine treatment: Progression-free survival

    PFS ist defined as time interval measured from the day of first vorasidenib administration to first progression or death, whichever comes first. Patients without tumor progression or death at the time of analysis will be censored at their date of last contact.

    Time frame: baseline, up to 72 months

  10. Assess effectiveness in routine treatment: Overall Survival (OS)

    OS is defined as the time interval measured form the day of first vorasidenib administration to time of death from any cause. Time to last contact will be used if a patient has no documented date of death and OS for the patient will be considered censored.

    Time frame: baseline, up to 72 months

  11. Assess effectiveness in routine treatment: Objective response rate (ORR)

    ORR is defined as the proportion of patients achieving Complete Response (CR), Partial Response (PR), or Minor Response (MR) as best response.

    Time frame: max. 72 months; from patient-specific study start to end of study (during vorasidenib treatment and follow-up)

  12. Assess effectiveness in routine treatment: Disease Control Rate (DCR)

    DCR is defined as proportion of patients with Complete Response, Partial Response, Minor Response or Stable Disease as best response.

    Time frame: baseline, up to 72 months

  13. Assess effectiveness in routine treatment: Best response

    Best response is defined as Complete Response (CR), Partial Response (PR), Minor Response (MR), Stable Disease (SD), or Progressive Disease (PD))

    Time frame: baseline, up to 72 months

  14. Assess effectiveness in routine treatment: Time to next intervention (TTNI)

    Time to next intervention is defined as time from first administration of vorasidenib until initiation of next intervention (i.e., subsequent antineoplastic treatment, surgery, chemotherapy or radiotherapy) or death, whichever comes first.

    Time frame: baseline, up to 72 months

  15. Assess drug safety: Incidence of (serious) adverse events ((S)AEs)

    Incidence of (serious) AEs ((S)AEs) as characterized by type, frequency, severity and seriousness.

    Time frame: Baseline up to 30 days after vorasidenib treatment

  16. Assess drug safety: Incidence of (serious) adverse drug reactions ((S)ADRs)

    Incidence of (serious) adverse drug reactions ((S)ADRs) as characterized by type, frequency, severity and seriousness.

    Time frame: Baseline up to 30 days after vorasidenib treatment

  17. Assess drug safety: Incidence of seizures reported as treatment-emergent adverse events (TEAEs)

    Treatment-emergent adverse events (TEAE) are adverse events that were not present before medical treatment, or a pre-existing event that worsens in intensity or frequency during vorasidenib treatment and the following 30 days.

    Time frame: Baseline up to 30 days after vorasidenib treatment

  18. Assess parameters of physicians' treatment decision making using a questionnaire

    Frequency of distinct parameters affecting therapy choice; questionnaire completed by treating physician.

    Time frame: Baseline

  19. Duration of treatment with vorasidenib

    Describe treatment reality in detail: Duration of treatment with vorasidenib

    Time frame: baseline, up to 72 months

  20. Frequency of treatment modifications with reasons

    Describe treatment reality in detail: Frequency of treatment modifications with reasons

    Time frame: baseline, up to 72 months

  21. Time to start of vorasidenib treatment after initial diagnosis

    Describe treatment reality in detail: Time to start of vorasidenib treatment after initial diagnosis

    Time frame: Baseline

  22. Time to start of vorasidenib treatment after surgery

    Describe treatment reality in detail: Time to start of vorasidenib treatment after surgery

    Time frame: Baseline

  23. Frequency of distinct subsequent antineoplastic therapies (systemic therapies including substances, surgeries, radiotherapies)

    Describe treatment reality in detail: Frequency of distinct subsequent antineoplastic therapies (systemic therapies including substances, surgeries, radiotherapies)

    Time frame: baseline, up to 72 months

  24. Anti-epileptic medication: Proportion of patients with anti-epileptic drug (AED) treatment at baseline

    Proportion of patients with anti-epileptic drug treatment at baseline (i.e. 30 days prior treatment)

    Time frame: baseline, up to 72 months

  25. Anti-epileptic medication: Proportion of patients with AED treatment during treatment

    Proportion of patients with anti-epileptic drug treatment during treatment

    Time frame: baseline, up to 72 months

  26. Anti-epileptic medication: Type of AED

    Anti-epileptic medication during course of treatment

    Time frame: baseline, up to 72 months

  27. Anti-epileptic medication: Doses of AED

    Doses of anti-epileptic medication over the course of time

    Time frame: baseline, up to 72 months

  28. Anti-epileptic medication: AED modifications

    Type of anti-epileptic medication modifications

    Time frame: baseline, up to 72 months

  29. Anti-epileptic medication: Reasons for AED modifications

    Anti-epileptic medication modifications with reasons thereof

    Time frame: baseline, up to 72 months

  30. Anti-epileptic medication: Frequency of patients under AED treatment after End of Treatment (EOT) of vorasidenib

    Frequency of patients under AED treatment after EOT of vorasidenib (incl. dose)

    Time frame: from end of treatment to end of study, up to 72 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Nov 2031, 71 months after the start.

Of 125 observational studies under Glioma, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 104. This study's planned 71 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2025
First posted
Nov 21, 2025
StartActual
Dec 8, 2025
Primary completionEst.
Nov 2031
CompletionEst.
Jan 2032
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07240662
Lead sponsor
iOMEDICO AG
Responsible party
Sponsor
First posted
Nov 21, 2025
Start date
Dec 8, 2025
Primary completion
Nov 2031 (estimated)
Completion
Jan 2032 (estimated)
Last update
Jan 9, 2026

Study contacts

iOMEDICO
Contact
information@iomedico.com
+49761152420

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion